Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies

ISSN: 1875-6638 (Online)
ISSN: 1573-4064 (Print)

Volume 13, 8 Issues, 2017

Download PDF Flyer

Medicinal Chemistry

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Honorary Life Fellow
Kings College
University of Cambridge

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 1.458
5 - Year: 1.423

Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies

Medicinal Chemistry, 10(7): 682-699.

Author(s): Georgios Bouras, Georgios Giannopoulos, George Hatzis, Dimitrios Alexopoulos, George Leventopoulos and Spyridon Deftereos.

Affiliation: Cardiology Department and Cardiac Catheterization Laboratory, Athens General Hospital “G. Gennimatas”, Mesogeion 154, 11527, Athens, Greece.


Heart failure (HF) is a complex heterogeneous syndrome with immune, metabolic and neurohumoral mechanisms interacting and leading to gradual heart contractility impairment. From the first study-to correlate inflammation with HF, inflammation biomarkers have been the subject of intense inquiry in patients with various forms of HF. Chronic HF (CHF) is strongly associated with inflammation in terms of pathogenesis, progression, severity and prognosis. Inflammatory mediators participate in CHF pathophysiology in various ways like exerting direct impact on cardiac myocytes, fibroblasts and β-adrenergic receptors leading to hypertrophy, fibrosis and impaired cardiac contractility, respectively, or inducing apoptosis by stimulation of the proper genes. The anti-inflammatory effects of classical heart failure therapeutic strategies such as ACEI and b-blockers are rather conflicting. Whether novel immunomodulating and anti-inflammatory therapeutic approaches should be added to existing therapies in order to ensure additional benefit to HF patients is under investigation. In this review, we summarize the pathophysiological link between inflammatory processes and CHF, focusing on the role of novel and traditional inflammatory biomarkers and highlighting novel anti-inflammatory therapeutic strategies.


Anti-TNF therapy, biomarkers, chemokines, CRP, heart failure, inflammation, interleukins, TNF- α.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 10
Issue Number: 7
First Page: 682
Last Page: 699
Page Count: 18
DOI: 10.2174/1573406410666140318113325
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science